This complements previous studies in DLBCL and MCL cell lines and a DLBCL mouse model that suggested potentiation of ibrutinib’s viability decreasing effects by downregulation of p-ERK-1/2 through inhibition of the MEK/ERK/AKT pathway [63]. This evidence concerns the gene AKT1 and diffuse large B-cell lymphoma.